Anbio Biotechnology Balance Sheet Health

Financial Health criteria checks 6/6

Anbio Biotechnology has a total shareholder equity of $30.2M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $30.2M and $87.8K respectively. Anbio Biotechnology's EBIT is $5.8M making its interest coverage ratio -27.5. It has cash and short-term investments of $11.9M.

Key information

Debt to equity ratio

US$0

Debt

Interest coverage ratio	-27.5x
Cash	US$11.90m
Equity	US$30.16m
Total liabilities	US$87.84k
Total assets	US$30.24m

Recent financial health updates

No updates

Recent updates

Seeking Alpha • Oct 10

Anbio Biotechnology's Hype And Hard Approvals Suggest A Stretched Valuation

Summary Anbio Biotechnology is a medical device firm specializing in in-vitro diagnostics, with recent stock volatility and a thin public float. I believe they continue to face significant regulatory hurdles in both the EU (IVDR transition) and the US (FDA clearance). Likewise, NNNN trades at an extremely high valuation relative to its fundamentals and peers. It also has concentrated voting control on Class B shares. Thus, agency risks, regulatory uncertainties, and an expensive valuation nudge me towards "Sell" on the stock. Read the full article on Seeking Alpha

Financial Position Analysis

Short Term Liabilities: NNNN's short term assets ($30.2M) exceed its short term liabilities ($87.8K).

Long Term Liabilities: NNNN has no long term liabilities.

Debt to Equity History and Analysis

Debt Level: NNNN is debt free.

Reducing Debt: NNNN has not had any debt for past 5 years.

Debt Coverage: NNNN has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: NNNN has no debt, therefore coverage of interest payments is not a concern.

Balance Sheet

Discover healthy companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/07/21 23:48
End of Day Share Price	2026/07/21 00:00
Earnings	2025/12/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Anbio Biotechnology is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.